Report Overview
The global hypertrophic and keloid scar treatment market size was valued at USD 6.34 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 8.47% from 2022 to 2030. The increase in the number of road accidents & burn cases, along with technological advancements and growing awareness regarding the availability of aesthetic surgery are major factors boosting the industry adoption over the years. The global increase in the number of road accidents & burn incidence is anticipated to boost the hypertrophic and keloid scar treatment market. For instance, according to Association for Safe International Road Travel, approximately 1.35 million people die in road accidents every year. Moreover, as per a similar source, in the U.S. 4.4 million people get seriously injured. Furthermore, according to the Ministry of Road Transport and Highways, India, a total of 449,002 accidents were recorded in India during the year 2019. Therefore, the global rise in the number of accidents is anticipated to propel the hypertrophic and keloid scar treatment market during the forecast period.
To learn more about this report,request a free sample copy
Additionally, as per a study conducted by Value in Health journal, around 12,946 people in Germany were reported with complex burn injuries. Similarly, according to a report by National Fire Protection Association, local fire departments responded to approximately 1.4 million fire incidences in the U.S. Moreover, as per American Burn Association, home fires were reported every year and more than 450,000 serious burn injuries are recorded in the U.S. alone.
Moreover, according to WHO, approximately 180,000 deaths due to burn incidence are recorded annually, out of which the majority of incidents are recorded in low- and middle-income countries. For instance, as per the National Health Portal of India, around 7 million people suffer from burn injuries every year. Thus, with rising burn cases, the global hypertrophic and keloid scar treatment market is estimated to impel over the forecast period.
Furthermore, technological advancement is expected to further boost the business margin. The introduction of laser therapies for treatment & elimination of scars is widely being adopted. Moreover, many companies are introducing new laser therapy products forscar treatment. For instance, Cynosure introduced a new generation MedLite C6 which is a Q-switched laser therapy device used to treat skin diseases.
In addition to this, growing awareness regarding the availability of aesthetic surgery is anticipated to impel market growth. For instance, according to the American Society of Plastic Surgeons (ASPS), approximately 18 million people had a surgical invasive cosmetic procedure in the U.S. in 2018. Similarly, as per a report published by Aesthetic Plastic Surgery National Databank, in 2020, the revenue of all aesthetic procedures was calculated to be USD 9.30 billion. These surgeries are focused on reconstructing body parts that have sustained damage due to burns & accidents. Thus, with the rising awareness about the availability of aesthetic surgery, the industry is sure to gain commendable profits in the ensuing years.
The COVID-19 pandemic was predicted to lower the use of hypertrophic and keloid scar treatment products to a certain extent. However, as the COVID-19 cases are reduced, and restrictions revoked, the procedure is anticipated to witness significant growth. To capture the post-pandemic market, many industry players are adopting various strategies such as geographic expansion, partnership, mergers & acquisitions. For instance, in December 2020, Molnlycke Health AB announced the launch of their new U.K. distribution center. This was intended to strengthen the company’s supply chain in the U.K. during the post-COVID-19 time. Therefore, such strategies initiated by several other companies are anticipated to impel the hypertrophic and keloid scar treatment market post-COVID-19 pandemic.
Scar Type Insights
Based on scar type, keloid scar dominated the market in 2021, with a total market share of 64.76%. Moreover, keloid scars are projected to witness the fastest growth rate at a CAGR of 8.78% during the forecast period. Keloid scars extend beyond the wound area and may become large. Furthermore, these scars are harder to heal and have a high return rate. For instance, as per Medscape, keloid scars treated with simple excision have a recurrence rate of 50-80%.
Additionally, keloid scars have a high risk of changing to cancer cells. On top of that, these scars do not heal on their own and never go away without treatment. Moreover, according to the American Osteopathic College of Dermatology, it is estimated that around 10% of people may witness keloid scars. Thus, due to the aforementioned factors, the keloid scar type is expected to dominate & witness the fastest growth rate over the forecast period.
However, the hypertrophic scar type is projected to witness a considerably slow growth rate during the forecast time. This can be attributed to the characteristics of hypertrophic scars. Hypertrophic scars stay within the wound area. Moreover, these are less frequently seen and easier to treat as compared to keloid scars. Furthermore, unlike keloid scars, hypertrophic scars may become less noticeable with time, as a result, many people avoid treating them. Hence, due to the above-mentioned factors, hypertrophic scars are anticipated to witness a comparatively slow growth rate.
Product Insights
Based on product, the topical segment held the largest market share of more than 40.00% in the product segment. This dominance can be attributed to the rising use of topical products such as creams, silicone sheets, and gels on hypertrophic & keloid scars. These topical products are simply available to customers as over-the-counter (OTC) products, as a result, these are bought frequently. Moreover, these products do not need a person to visit any physicians for medication, thus, has become an easy and affordable alternative. Therefore, due to the aforementioned factors, the topical products segment is anticipated to dominate the industry during the period in focus.
However, the laser segment is projected to witness the fastest growth rate over the forecast period. This can be attributed to the advantages laser treatment provide to a patient. For instance, laser treatment resolves deep pitting and scarring. Moreover, the laser treatment is less harsh than traditional methods and is safe for all skin types & scar types. Furthermore, a study conducted at Medscape reported an average improvement of 77% after 1.8 laser treatments of hypertrophic scars. Thus, owing to the above-mentioned reasons, the laser product treatment is estimated to witness the fastest growth rate over the forecast period.
End-use Insights
Based on end-use, the hospitals segment dominated the hypertrophic and keloid scar treatment market with a market share of more than 43.00% in the year 2021. This can be credited to an increase in the number of hospital admissions and a rise in the number of hospitals globally. For instance, as per a study published by the American Hospital Association 2022 edition, the hospital count in the U.S. was calculated to be approximately 6,093 in 2020.
Similarly, as per the Centers for Disease Control and Prevention, the emergency department visit rate in the U.S. due to motor vehicle crashes was estimated to be 5.3 visits per 1,000 persons. Thus, with such an increase in the number of hospitals & hospital admissions due to road accidents, the hypertrophic and keloid scar treatment market is anticipated to propel over the forecast period.
To learn more about this report,request a free sample copy
The retail pharmacies/e-commerce segment is projected to have the fastest growth rate over the projected duration. This can be attributed to the nature of the availability of products. For instance, products such as creams, gels, and silicone sheets are categorized as over-the-counter products. These products are readily & easily available, without any prescription from a physician.
Moreover, companies across the globe are partnering with variouse-commercesites such as Amazon. For instance, in September 2021, Sanoma Pharmaceuticals partnered with Amazon to provide hypertrophic and keloid scar treatment products in the U.S. Thus, such instances are anticipated to drive the retail pharmacies/e-commerce segment over the forecast period.
Regional Insights
North America dominated the market with a market share of 34.65% in 2021. This can be attributed to the rising incidence rate of accidents in this region. Moreover, an increase in skin-related disorders is further expected to drive the market scope in the North America region. For instance, according to the Canadian Dermatology Association, acne affects approximately 5.6 million Canadians, which is about 20% of the total population.
Similarly, as per Colorado Springs Dermatology Clinic, acne affects roughly 40-50 million people annually in the U.S. The healing process of acne leads to the formation of hypertrophic & keloid scars. Hence, a rise in the number of skin disorders such as acne formation is anticipated to propel the use of the treatment in this region.
Asia Pacific is projected to witness the fastest growth rate of a CAGR of 9.68% during the forecast years. This can be attributed to the increase in the number of burn cases along with the presence of a wide population suffering from skin disorders such as acne. Furthermore, a rise in aesthetic surgery in this region is anticipated to drive the market expansion in this region. For instance, as per the National Library of Medicine, India ranked fifth in the number of aesthetic surgeries performed globally. A total of 895,896 non-surgical & surgical procedures were conducted in India, including 54,234 rhinoplasties, which was only second to Brazil. Moreover, as per a similar source, East Asia has shown great potential & is the fastest growing market for aesthetic surgery worldwide.
Key Companies & Market Share Insights
The market is highly fragmented in nature with the presence of numerous market players. Competitive rivalry & degree of competition in the hypertrophic and keloid scar market is expected to intensify over the forecast period. Moreover, to capture the market, many market players are entering into various strategic initiatives such as mergers & acquisitions, expansion, and product launches. For instance, in February 2020, Sonoma Pharmaceuticals, Inc. announced an asset purchase agreement with Middle East partner MicroSafe Group. Under this agreement, Sanoma Pharmaceuticals purchased certain wound care, disinfection, and animal health care products in Australia, Europe & Middle East for USD 1.1 million from MicroSage Group. Thus, with various strategies adopted by key market players, the hypertrophic and keloid scar treatment market is predicted to impel during the forecast period. Some key players in the global hypertrophic and keloid scar treatment market include:
Smith & Nephew
Merz Pharmaceuticals, LLC
Lumenis
Enaltus LLC
Sonoma Pharmaceuticals, Inc.
Molnlycke Health Care AB
Suneva Medical, Inc.
Pacific World Corporation
Perrigo Company PLC
Cynosure, Inc.
Alliance Pharma, PLC
Newmedical Technology, Inc.
Hypertrophic And Keloid Scar Treatment Market Report Scope
| Report Attribute | Details |
|---|
Market size value in 2022 | USD 7.62 billion |
Revenue forecast in 2030 | USD 14.60 billion |
Growth Rate | CAGR of 8.47% from 2022 to 2030 |
Base year for estimation | 2021 |
Historical data | 2018 - 2020 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million and CAGR from 2022 to 2030 |
Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered | Scar type, product, end-use, region |
Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA) |
Country scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Brazil; Mexico; Argentina; Colombia; South Africa; Saudi Arabia; UAE. |
Key companies profiled | Smith & Nephew; Merz Pharmaceuticals, LLC.; Lumenis, Enaltus LLC; Sonoma Pharmaceuticals, Inc.; Molnlycke Health Care AB; Suneva Medical, Inc.; Pacific World Corporation; Perrigo Company PLC; Cynousre, Inc; Alliance Pharma, PLC.; Newmedical Technology, Inc; |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
|
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global hypertrophic and keloid scar treatment market report based on scar type, products, end-use, and region:
Scar type Outlook (Revenue, USD Million, 2018 - 2030)
Hypertrophic Scars
Keloid Scars
Product Outlook (Revenue, USD Million, 2018 - 2030)
Topical Products
Creams
Gels
Silicone Sheets
Others
Laser Products
Pulse-dyed Lasers
CO2Lasers
Others
Injectables
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Argentina
Mexico
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Frequently Asked Questions About This Report
